Damora Therapeutics

Damora Therapeutics is an innovative biotechnology company advancing a new generation of disease-modifying biologics to redefine care for people with hematologic disorders. The company is focused on mutant calreticulin-driven myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET) and myelofibrosis (MF). Its lead program, DMR-001, is an investigational monoclonal antibody designed to selectively target mutant calreticulin. Damora was originally founded on assets developed by Paragon Therapeutics and was acquired by Galecto, Inc. in November 2025 in a transaction valued at $285 million. In March 2026, Galecto formally changed its name to Damora Therapeutics and began trading on Nasdaq under the ticker DMRA.